Clinical trial
Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in…
NCT00191659 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191659 |
|---|---|
| Title | Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/Adolescents |
| Official title | A Randomised, Controlled, Open-Label Study of the Broader Efficacy of Atomoxetine Hydrochloride in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Attention Deficit Hyperactivity Disorder |
| Intervention type | Drug |
| Interventions | Atomoxetine Hydrochloride |
| Enrollment | 200 |
| Start date | Jun 1, 2004 |
| Completion | Apr 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Mar 2, 2007 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: